Ces radiol. 2021, 75(3):247-256 | DOI: 10.55095/CesRadiol2021/031

Multiparametric magnetic resonance imaging in the diagnosis of bladder cancer - VI-RADSOriginal article

Pavla Hanzlíková1, Kateřina Ryšánková2, Vladimír Židlík3
1 Ústav radiodiagnostický FN, Ostrava
2 Urologická klinika FN, Ostrava
3 Ústav patologie FN, Ostrava

The paper aims to present the current approach to the evaluation of bladder tumours using magnetic resonance imaging. The authors give a newly implemented system for scoring bladder wall involvement and provide an overview of the recommended techniques in the multiparametric examination for the VI-RADS system. This system of scoring bladder cancer involvement has been mentioned in the guidelines of the European Urological Association as an effective tool for distinguishing the depth of bladder tumour invasion.
Part of the article is a recommended examination scheme valid for 1.5 T and 3 T magnetic resonance devices.
The next part presents the VI-RADS system, its components and the method of evaluation, distinguishing advanced bladder tumours from less severe findings. The article includes MR scans obtained by applying the VI-RADS examination system.
The discussion evaluates the effect of the VI-RADS system, its potential limitations and challenges.

Keywords: magnetic resonance imaging, bladder, bladder cancer, VI-RADS
Grants and funding:

Implementace systému VI-RADS pro použití ve Fakultní nemocnici Ostrava je podpořeno projektem MZ ČR - RVO (RVO-FNOs/2020 - FN Ostrava, IČ 00843989), zahájeno v roce 2020.

Accepted: September 15, 2021; Published: September 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hanzlíková P, Ryšánková K, Židlík V. Multiparametric magnetic resonance imaging in the diagnosis of bladder cancer - VI-RADS. Ces radiol. 2021;75(3):247-256. doi: 10.55095/CesRadiol2021/031.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424. doi: 10.3322/caac.21492 Go to original source... Go to PubMed...
    2. Zhu CZ, Ting HN, Ng KH, Ong TA. A review on the accuracy of bladder cancer detection methods. J Cancer 2019; 10(17): 4038-4044. doi: 10.7150/jca.28989 Go to original source... Go to PubMed...
    3. Verma S, Rajesh A, Prasad SR, Gaitonde K, Lall CG, et al. Urinary bladder cancer: role of MR imaging. Radiographics 2012; 32(2): 371-387. doi: 10.1148/rg.322115125 Go to original source... Go to PubMed...
    4. Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, Malats N. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol 2007; 25(3): 285-295. doi: 10.1007/s00345-007-0168-5 Go to original source... Go to PubMed...
    5. Anderson B, Naish W. Bladder cancer and smoking. Part 2: diagnosis and management. Br J Nurs 2008; 17(19): 1240-1245. doi: 10.12968/bjon.2008.17.19.31466 Go to original source... Go to PubMed...
    6. Josephson D, Pasin E, Stein JP. Superficial bladder cancer: part 2. Management. Expert Rev Anticancer Ther 2007; 7(4): 567-581. doi: 10.1586/14737140.7.4.567 Go to original source... Go to PubMed...
    7. Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and carcinoma in situ) - 2019 Update. Eur Urol 2019; 76(5): 639-657. doi: 10.1016/j.eururo.2019.08.016 Go to original source... Go to PubMed...
    8. Pecoraro M, Takeuchi M, Vargas HA, Muglia VF, Cipollari S, et al. Overview of VI-RADS in Bladder Cancer. AJR Am J Roentgenol 2020; 214(6): 1259-1268. doi: 10.2214/AJR.20.22763 Go to original source... Go to PubMed...
    9. Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol 2018; 74(3): 294-306. doi: 10.1016/j.eururo.2018.04.029 Go to original source... Go to PubMed...
    10. Lazica DA, Roth S, Brandt AS, Böttcher S, Mathers MJ, et al. Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. Urol Int 2014; 92(2): 131-135. doi: 10.1159/000353089 Go to original source... Go to PubMed...
    11. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007; 51(1): 137-149; discussion 149-151. doi: 10.1016/j.eururo.2006.05.021 Go to original source... Go to PubMed...
    12. Richterstetter M, Wullich B, Amann K, Haeberle L, Engehausen DG, et al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. BJU Int 2012; 110(2 Pt 2): E76-79. doi: 10.1111/j.1464-410X.2011.10904.x Go to original source... Go to PubMed...
    13. Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 2021; 79(1): 82-104. doi: 10.1016/j.eururo.2020.03.055 Go to original source... Go to PubMed...
    14. Narumi Y, Kadota T, Inoue E, Kuriyama K, Horinouchi T, et al. Bladder wall morphology: in vitro MR imaging-histopathologic correlation. Radiology 1993; 187(1): 151-155. doi: 10.1148/radiology.187.1.8451403 Go to original source... Go to PubMed...
    15. Narumi Y, Kadota T, Inoue E, Kuriyama K, Fujita M, Hosomi N, Sawai YK, et al. Bladder tumors: staging with gadolinium-enhanced oblique MR imaging. Radiology 1993; 187(1): 145-150. doi: 10.1148/radiology.187.1.8451401 Go to original source... Go to PubMed...
    16. Thoeny HC, Bellin MF, Comperat EM, Thalmann GN. Vesical Imaging-Reporting and Data System (VI-RADS): Added Value for Management of Bladder Cancer Patients? Eur Urol 2018; 74(3): 307-308. doi: 10.1016/j.eururo.2018.06.017 Go to original source... Go to PubMed...
    17. Paner GP, Montironi R, Amin MB. Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. Adv Anat Pathol 2017; 24(3): 113-127. doi: 10.1097/PAP.0000000000000152 Go to original source... Go to PubMed...
    18. Wang HJ, Pui MH, Guan J, Li SR, Lin JH, et al. Comparison of Early Submucosal Enhancement and Tumor Stalk in Staging Bladder Urothelial Carcinoma. AJR Am J Roentgenol 2016; 207(4): 797-803. doi: 10.2214/AJR.16.16283 Go to original source... Go to PubMed...
    19. Del Giudice F, Barchetti G, De Berardinis E, Pecoraro M, Salvo V, et al. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection. Eur Urol 2020; 77(1): 101-109. doi: 10.1016/j.eururo.2019.09.029 Go to original source... Go to PubMed...
    20. Zhou G, Chen X, Zhang J, Zhu J, Zong G, Wang Z. Contrast-enhanced dynamic and diffusion-weighted MR imaging at 3.0T to assess aggressiveness of bladder cancer. Eur J Radiol 2014; 83(11): 2013-2018. doi: 10.1016/j.ejrad.2014.08.012 Go to original source... Go to PubMed...
    21. Panebianco V, De Berardinis E, Barchetti G, Simone G, Leonardo C, et al. An evaluation of morphological and functional multiparametric MRI sequences in classifying non-muscle and muscle invasive bladder cancer. Eur Radiol 2017; 27(9): 3759-3766. doi: 10.1007/s00330-017-4758-3 Go to original source... Go to PubMed...
    22. Erkoc M, Otunctemur A, Bozkurt M, Can O, Atalay HA, et al. The efficacy and reliability of VI-RADS in determining candidates for repeated transurethral resection in patients with high-risk non-muscle invasive bladder cancer. Int J Clin Pract 2021: e14584. doi: 10.1111/ijcp.14584 Go to original source... Go to PubMed...
    23. Makboul M, Farghaly S, Abdelkawi IF. Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application. Br J Radiol 2019; 92(1104): 20190401. doi: 10.1259/bjr.20190401 Go to original source... Go to PubMed...
    24. Takeuchi M, Sasaki S, Naiki T, Kawai N, Kohri K, et al. MR imaging of urinary bladder cancer for T-staging: a review and a pictorial essay of diffusion-weighted imaging. J Magn Reson Imaging 2013; 38(6): 1299-1309. doi: 10.1002/jmri.24227 Go to original source... Go to PubMed...
    25. Woo S, Panebianco V, Narumi Y, Del Giudice F, Muglia VF, et al. Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol 2020; 3(3): 306-315. doi: 10.1016/j.euo.2020.02.007 Go to original source... Go to PubMed...
    26. Fragkoulis C, Glykas I, Papadopoulos G, Ntoumas K. Multiparametric MRI in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer with vesical imaging reporting and data system (VI-RADS) application. Br J Radiol 2020; 93(1109): 20200025. doi: 10.1259/bjr.20200025 Go to original source... Go to PubMed...
    27. Hechler V, Rink M, Beyersdorff D, Beer M, Beer AJ, P, et al. The role of the vesical imaging-reporting and data system (VI-RADS) for bladder cancer diagnostics - status quo]. Urologe A 2019; 58(12): 1443-1450. doi: 10.1007/s00120-019-0106-3 Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content